Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +43.70% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.21 | N/A | +43.70% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on their pipeline and upcoming trials. They did not provide specific guidance for future performance.
Management expressed confidence in ongoing projects and their potential impact.
They highlighted the importance of upcoming trials in shaping future results.
Nektar Therapeutics reported a narrower loss than expected, but the lack of revenue details may have raised concerns among investors. The stock reacted negatively, dropping 6.42%. Investors will be watching closely for updates on the company's ongoing projects and trials, which management believes are crucial for future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Oct 31, 2011